These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7902778)

  • 1. 3rd International Workshop on Randomized Trials on Maximal Androgen Blockade in M1 Prostate Cancer Patients. Proceedings. Paris, France, June 19, 1992.
    Cancer; 1993 Dec; 72(12 Suppl):3781-895. PubMed ID: 7902778
    [No Abstract]   [Full Text] [Related]  

  • 2. [Complete androgen blockage in the treatment of metastatic prostate cancer].
    Matzkin H; Braf Z
    Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
    [No Abstract]   [Full Text] [Related]  

  • 3. Docetaxel for hormone-sensitive metastatic prostate cancer.
    Baker H
    Lancet Oncol; 2015 Sep; 16(9):e432. PubMed ID: 26278160
    [No Abstract]   [Full Text] [Related]  

  • 4. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
    Matveev BP; Bukharkin BV
    Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will chemotherapy change the management of prostate cancer?
    Gilson C; Sydes MR; Chowdhury S
    BJU Int; 2016 Aug; 118(2):190-2. PubMed ID: 26696125
    [No Abstract]   [Full Text] [Related]  

  • 6. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
    Rusakov IG; Alekseev BIa
    Urologiia; 2002; (5):23-6. PubMed ID: 12402771
    [No Abstract]   [Full Text] [Related]  

  • 7. New agents in metastatic prostate cancer.
    Fizazi K; Massard C
    Eur J Cancer; 2009 Sep; 45 Suppl 1():379-80. PubMed ID: 19775638
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED.
    Aragon-Ching JB
    Asian J Androl; 2016; 18(3):444-5. PubMed ID: 26510505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
    Martorana G
    Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate cancer. Endocrine and cytotoxic therapy.
    Smith PH
    Recent Results Cancer Res; 1981; 78():154-72. PubMed ID: 7022593
    [No Abstract]   [Full Text] [Related]  

  • 11. Abiraterone and increased survival in metastatic prostate cancer.
    Sonpavde G
    N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
    [No Abstract]   [Full Text] [Related]  

  • 12. New drug for prostate cancer.
    Eur J Cancer Care (Engl); 2001 Jun; 10(2):79-80. PubMed ID: 11829051
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel concepts in androgen receptor blockade.
    Hsieh AC; Ryan CJ
    Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?
    Akaza H
    Can J Urol; 2005 Feb; 12 Suppl 1():77-80. PubMed ID: 15780172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A one-two punch against prostate cancer.
    Johns Hopkins Med Lett Health After 50; 2014 Mar; 26(1):8. PubMed ID: 24937853
    [No Abstract]   [Full Text] [Related]  

  • 16. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP; Bukharkin BV
    Urologiia; 2003; (6):6-10. PubMed ID: 14708235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of advanced cancer of the prostate.
    Wirth MP
    Prog Clin Biol Res; 1990; 350():159-70. PubMed ID: 2201042
    [No Abstract]   [Full Text] [Related]  

  • 18. New avenues and perspectives in the management of advanced prostate cancer. Proceedings of a symposium. Paris, France, September 1, 1996.
    Eur Urol; 1997; 31 Suppl 2():1-39. PubMed ID: 9074902
    [No Abstract]   [Full Text] [Related]  

  • 19. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
    Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.